Your browser doesn't support javascript.
loading
Lineage tracing reveals clonal progenitors and long-term persistence of tumor-specific T cells during immune checkpoint blockade.
Pai, Joy A; Hellmann, Matthew D; Sauter, Jennifer L; Mattar, Marissa; Rizvi, Hira; Woo, Hyung Jun; Shah, Nisargbhai; Nguyen, Evelyn M; Uddin, Fathema Z; Quintanal-Villalonga, Alvaro; Chan, Joseph M; Manoj, Parvathy; Allaj, Viola; Baine, Marina K; Bhanot, Umesh K; Jain, Mala; Linkov, Irina; Meng, Fanli; Brown, David; Chaft, Jamie E; Plodkowski, Andrew J; Gigoux, Mathieu; Won, Helen H; Sen, Triparna; Wells, Daniel K; Donoghue, Mark T A; de Stanchina, Elisa; Wolchok, Jedd D; Loomis, Brian; Merghoub, Taha; Rudin, Charles M; Chow, Andrew; Satpathy, Ansuman T.
Afiliación
  • Pai JA; Department of Pathology, Stanford University, Stanford, CA, USA; Immunology Program, Stanford University, Stanford, CA, USA.
  • Hellmann MD; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA; Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Sauter JL; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Mattar M; Antitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Rizvi H; Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Woo HJ; Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Shah N; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Nguyen EM; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Cancer Biology Program, Louis V. Gerstner Jr. Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Uddin FZ; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Quintanal-Villalonga A; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Chan JM; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Manoj P; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Allaj V; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Baine MK; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Bhanot UK; Precision Pathology Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Jain M; Precision Pathology Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Linkov I; Precision Pathology Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Meng F; Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Brown D; Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Chaft JE; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA.
  • Plodkowski AJ; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Gigoux M; Ludwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Won HH; Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Sen T; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA.
  • Wells DK; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA; Santa Ana Bio, Alameda, CA, USA.
  • Donoghue MTA; Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • de Stanchina E; Antitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Wolchok JD; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA; Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Ludwig Collaborative and Swim Across America Laboratory, Memorial
  • Loomis B; Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Merghoub T; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA; Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Ludwig Collaborative and Swim Across America Laboratory, Memorial
  • Rudin CM; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA; Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Chow A; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA; Ludwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: chowa1@mskcc.org.
  • Satpathy AT; Department of Pathology, Stanford University, Stanford, CA, USA; Immunology Program, Stanford University, Stanford, CA, USA; Gladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA; Stanford Cancer Institute, Stanford University, Stanford, CA, USA; Parker Institute for Cancer Immunoth
Cancer Cell ; 41(4): 776-790.e7, 2023 04 10.
Article en En | MEDLINE | ID: mdl-37001526
Paired single-cell RNA and T cell receptor sequencing (scRNA/TCR-seq) has allowed for enhanced resolution of clonal T cell dynamics in cancer. Here, we report a scRNA/TCR-seq analysis of 187,650 T cells from 31 tissue regions, including tumor, adjacent normal tissues, and lymph nodes (LN), from three patients with non-small cell lung cancer after immune checkpoint blockade (ICB). Regions with viable cancer cells are enriched for exhausted CD8+ T cells, regulatory CD4+ T cells (Treg), and follicular helper CD4+ T cells (TFH). Tracking T cell clonotypes across tissues, combined with neoantigen specificity assays, reveals that TFH and tumor-specific exhausted CD8+ T cells are clonally linked to TCF7+SELL+ progenitors in tumor draining LNs, and progressive exhaustion trajectories of CD8+ T, Treg, and TFH cells with proximity to the tumor microenvironment. Finally, longitudinal tracking of tumor-specific CD8+ and CD4+ T cell clones reveals persistence in the peripheral blood for years after ICB therapy.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 6_ODS3_enfermedades_notrasmisibles Problema de salud: 6_other_respiratory_diseases / 6_trachea_bronchus_lung_cancer Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Neoplasias Pulmonares Límite: Humans Idioma: En Revista: Cancer Cell Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 6_ODS3_enfermedades_notrasmisibles Problema de salud: 6_other_respiratory_diseases / 6_trachea_bronchus_lung_cancer Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Neoplasias Pulmonares Límite: Humans Idioma: En Revista: Cancer Cell Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos
...